Faron Pharmaceuticals OyLSE:FARN 22 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, Faron Pharmaceuticals Oy ranks worse than 136425.51% on this metric.
LSE:FARN's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9 * Ranked among companies with meaningful Gross Margin % only.
Faron Pharmaceuticals Oy had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Faron Pharmaceuticals Oy (LSE:FARN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Faron Pharmaceuticals Oy had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Faron Pharmaceuticals Oy Gross Margin % Related Terms
Faron Pharmaceuticals Oy Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FARN vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Faron Pharmaceuticals Oy (LSE:FARN) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Faron Pharmaceuticals Oy and its competitors. Over the past decade, Faron Pharmaceuticals Oy's Gross Margin % has ranged from 121.14 to 121.14. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 733 companies in the Biotechnology industry.
Is Faron Pharmaceuticals Oy's Gross Margin % too high?
Faron Pharmaceuticals Oy's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 121.14 to a high of 121.14. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 733 companies for Gross Margin %. This places Faron Pharmaceuticals Oy in the lower half of its industry. The industry median Gross Margin % is 60.90. Historically, Faron Pharmaceuticals Oy's own Gross Margin % has ranged from 121.14 to 121.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Faron Pharmaceuticals Oy and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faron Pharmaceuticals Oy's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (LSE:FARN) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score
Get the complete analysis for LSE:FARN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FARN has been successfully added to your 
